A discovery that benefit the common diseasesToday ELA is even prouder of this result because this innovative approach opens up perspectives in treating other types of leukodystrophies and damage foundation founded in 2005. Supported by the French Ministry for Research Allows the Foundation’s efforts and momentum reserved 30 million euros for all types of leukodystrophies.

Accompanying ELA cares for patients and brings special attention to those who benefit from research benefit from research advances. That’s why ELA commits 4.3 million euros to support the patient and family needs. With the same motivations, ELA supports the development of similar organizations in Europe .Alteon investigational drug alagebrium demonstrates the capability to the Functional Membrane Transport in a rat model chronic peritoneal enhancing.

Other Posts From "venereology":

Related Posts